ENFN Stock Price, Enfusion, Inc. Quote, Chart

Market Summary

USD9.53+0.02

Market Closed

0.21%

ENFN Stock Price

View Fullscreen

ENFN RSI Chart

ENFN Valuation

Market Cap

840.6M

Price/Earnings (Trailing)

139.51

Price/Sales (Trailing)

4.82

EV/EBITDA

37.49

Price/Free Cashflow

39.68

ENFN Price/Sales (Trailing)

ENFN Profitability

Operating Margin

66.97%

EBT Margin

6.58%

Return on Equity

11.23%

Return on Assets

5.53%

Free Cashflow Yield

2.52%

ENFN Fundamentals

ENFN Revenue

Revenue (TTM)

174.5M

Rev. Growth (Yr)

14.73%

Rev. Growth (Qtr)

4.8%

ENFN Earnings

Earnings (TTM)

6.0M

Earnings Growth (Yr)

26.11%

Earnings Growth (Qtr)

-65.92%

Breaking Down ENFN Revenue

Last 7 days

1.2%

Last 30 days

3.6%

Last 90 days

21.4%

Trailing 12 Months

13.5%

How does ENFN drawdown profile look like?

ENFN Financial Health

Current Ratio

3.44

ENFN Investor Care

Shares Dilution (1Y)

3.29%

Diluted EPS (TTM)

0.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	157.2M	163.4M	168.6M	174.5M
2022	121.5M	131.6M	141.7M	150.3M
2021	87.6M	95.6M	103.7M	111.7M
2020	0	0	0	79.6M
2019	0	0	0	59.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Enfusion, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	movchan oleg	acquired	-	-	249,701	chief executive officer
Mar 01, 2024	gutowski valeria	sold (taxes)	-9,112	8.67	-1,051	chief accounting officer
Mar 01, 2024	bastone bronwen	acquired	45,162	0.411267	109,812	chief people officer
Mar 01, 2024	herring bradley	acquired	82,763	0.966066	85,671	chief financial officer
Mar 01, 2024	gutowski valeria	acquired	26,322	1.29423	20,338	chief accounting officer
Mar 01, 2024	herring bradley	sold (taxes)	-20,157	8.67	-2,325	chief financial officer
Mar 01, 2024	movchan oleg	sold (taxes)	-35,278	8.67	-4,069	chief executive officer
Mar 01, 2024	movchan oleg	acquired	120,400	8.67	13,887	chief executive officer
Mar 01, 2024	campobasso matthew	acquired	27,085	1.03406	26,193	general counsel
Mar 01, 2024	pawar neal	acquired	-	-	144,176	chief operating officer

Which funds bought or sold ENFN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Migdal Insurance & Financial Holdings Ltd.	added	62.3	1,000	2,000	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	unchanged	-	5,427	140,412	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	64.00	64.00	-%
Apr 29, 2024	Allspring Global Investments Holdings, LLC	new	-	44,141	44,141	-%
Apr 29, 2024	PRINCIPAL FINANCIAL GROUP INC	new	-	452,446	452,446	-%
Apr 25, 2024	Allworth Financial LP	new	-	463	463	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-8.02	-159,779	1,140,510	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	-3,032	62,327	-%
Apr 24, 2024	Simplicity Wealth,LLC	new	-	175,741	175,741	-%

Are Funds Buying or Selling ENFN?

Are funds buying ENFN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENFN

No. of Funds

Unveiling Enfusion, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	brown capital management llc	14.03%	11,817,661	SC 13G/A
Feb 14, 2024	csl tech holdings llc	13.6%	13,768,183	SC 13G/A
Feb 14, 2024	werner capital llc	5.04%	4,682,016	SC 13G/A
Feb 14, 2024	iconiq strategic partners v, l.p.	8.8%	7,748,000	SC 13G/A
Feb 14, 2024	dragoneer investment group, llc	0%	0	SC 13G/A
Feb 07, 2024	lra ventures, llc	8.46%	7,972,007	SC 13G/A
Jan 19, 2024	malherbe investments llc	10.06%	9,870,386	SC 13G/A
Jun 23, 2023	ftv iv, l.p.	1.48%	31,297,606	SC 13D
Mar 09, 2023	brown capital management llc	10.50%	7,244,171	SC 13G/A
Feb 14, 2023	brown capital management llc	8.70%	6,001,842	SC 13G/A

Recent SEC filings of Enfusion, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 19, 2024	8-K	Current Report
Mar 12, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Mar 12, 2024	S-8	Employee Benefits Plan
Mar 07, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Enfusion, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
CRM	264.0B	34.9B	-10.48%	41.29%	63.82	7.57	11.18%	1888.46%
UBER	142.4B	37.3B	-10.92%	81.21%	75.46	3.82	16.95%	120.64%
ADSK	44.9B	5.3B	-15.58%	8.39%	48.98	8.4	9.15%	48.14%
ANSS	27.5B	2.2B	-9.04%	2.12%	63.19	12.33	3.59%	-21.47%
ZM	18.9B	4.5B	-1.49%	3.30%	29.64	4.17	3.06%	514.65%
MID-CAP
APPF	8.5B	671.8M	0.13%	72.75%	111.39	12.68	33.64%	185.98%
LYFT	6.5B	4.4B	-9.36%	54.64%	-19.07	1.47	7.53%	78.52%
AYX	3.4B	970.0M	0.90%	-15.87%	-19.13	3.53	13.46%	43.89%
ALRM	3.4B	881.7M	-3.56%	49.03%	42.12	3.84	4.64%	44.42%
AI	2.8B	296.4M	-10.13%	33.05%	-10.26	9.41	11.14%	-3.59%
AGYS	2.3B	228.1M	1.07%	7.63%	25.98	9.94	18.99%	599.09%
SMALL-CAP
AVID	1.2B	413.5M	0.63%	-1.64%	92.02	2.88	-1.65%	-71.35%
APPS	206.1M	572.4M	-14.41%	-82.25%	-1.04	0.36	-19.38%	-489.49%
ASUR	205.5M	117.7M	7.42%	-43.22%	-20.84	1.75	12.54%	11.24%
AEYE	201.6M	31.6M	82.32%	168.53%	-34.33	6.37	2.76%	43.72%

Enfusion, Inc. News

Latest updates

Enfusion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Revenue	4.8%	46,486	44,357	42,721	40,971	40,517	39,151	36,540	34,141	31,853	29,045	26,449	24,353	-	-
Cost Of Revenue	7.7%	15,624	14,507	14,208	13,302	13,296	11,974	10,847	10,983	10,164	8,095	6,777	6,809	-	-
Gross Profit	3.4%	30,862	29,850	28,513	27,669	27,221	27,177	25,693	23,158	21,689	20,950	19,672	17,544	-	-
Operating Expenses	5.8%	28,728	27,161	26,067	22,990	25,849	24,236	29,599	35,529	314,188	16,047	13,762	11,741	-	-
S&GA Expenses	0.9%	5,552	5,503	5,277	4,086	6,001	7,278	7,575	8,432	39,402	4,901	4,264	3,158	-	-
EBITDA Margin	11.1%	0.12*	0.11*	0.11*	0.08*	-0.04*	-2.12*	-2.28*	-2.39*	-2.44*	0.08*	0.09*	0.09*	0.10*	0.25*
Interest Expenses	-	-	-	-	-	-	4.00	1.00	6.00	526	1,485	1,410	1,392	-	-
Income Taxes	248.8%	1,280	367	188	396	418	287	219	150	-125	154	249	302	-	-
Earnings Before Taxes	-28.0%	2,180	3,028	1,186	5,090	1,206	2,885	-3,906	-12,374	-294,020	3,447	4,500	4,411	-	-
EBT Margin	5.5%	0.07*	0.06*	0.06*	0.03*	-0.08*	-2.17*	-2.33*	-2.46*	-2.52*	0.04*	0.05*	0.05*	0.06*	0.22*
Net Income	-65.9%	623	1,828	629	2,945	494	1,539	-2,422	-7,265	-169,969	3,293	4,251	4,109	-	-
Net Income Margin	-1.3%	0.03*	0.03*	0.03*	0.02*	-0.05*	-1.26*	-1.34*	-1.40*	-1.42*	0.04*	0.04*	0.05*	0.05*	0.21*
Free Cashflow	0.1%	9,509	9,499	3,799	-1,626	5,775	6,920	798	-7,268	-7,453	-4,281	4,987	-1,585	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q3	2021Q2	2020Q4
Assets	7.1%	109	102	94.00	121	124	116	110	105	106	89.00	73.00	56.00	39.00
Current Assets	12.6%	70.00	62.00	60.00	87.00	97.00	96.00	90.00	86.00	90.00	36.00	-	-	29.00
Cash Equivalents	12.5%	36.00	32.00	28.00	55.00	63.00	64.00	57.00	56.00	64.00	8.00	-	0.00	14.00
Net PPE	1.0%	18.00	18.00	18.00	17.00	16.00	15.00	16.00	15.00	13.00	12.00	-	-	9.00
Liabilities	10.6%	31.00	28.00	22.00	22.00	20.00	12.00	10.00	8.00	9.00	109	-	-	107
Current Liabilities	24.0%	20.00	16.00	14.00	14.00	17.00	12.00	10.00	8.00	8.00	16.00	-	-	11.00
Shareholder's Equity	5.8%	54.00	51.00	72.00	99.00	65.00	103	100	97.00	97.00	0.00	-	0.00	-233
Retained Earnings	0.4%	-172	-173	-175	-176	-178	-179	-180	-178	-171	-	-	-	-
Additional Paid-In Capital	1.0%	227	225	224	240	244	241	241	234	227	-	-	-	-
Shares Outstanding	0.0%	88.00	88.00	88.00	89.00	85.00	85.00	84.00	83.00	83.00	-	-	-	-
Minority Interest	5.6%	24.00	23.00	24.00	35.00	38.00	42.00	41.00	42.00	42.00	-	-	-	-
Float	-	-	-	438	-	-	-	258	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-45.6%	6,586	12,106	6,018	924	7,521	7,842	2,890	-4,097	-5,812	-2,309	7,036	767	-	-	-
Share Based Compensation	29.8%	3,404	2,623	2,578	-1,147	4,205	438	7,668	12,682	-	-	-	-	-	-	-
Cashflow From Investing	12.0%	-2,295	-2,607	-2,219	-2,550	-1,746	-922	-2,092	-3,171	-1,641	-1,972	-2,049	-2,352	-	-	-
Cashflow From Financing	89.1%	-579	-5,309	-30,842	-6,353	-7,042	-20.00	-92.00	-805	63,382	-1,788	-2,581	-164	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENFN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
REVENUES:
Total revenues	$ 174,535	$ 150,349	$ 111,700
COST OF REVENUES:
Total cost of revenues	57,641	47,100	31,845
Gross profit	116,894	103,249	79,855
OPERATING EXPENSES:
General and administrative	64,635	68,764	150,614
Sales and marketing	20,418	29,286	51,725
Technology and development	19,893	17,163	153,400
Total operating expenses	104,946	115,213	355,739
Income (loss) from operations	11,948	(11,964)	(275,884)
NON-OPERATING INCOME (EXPENSE):
Payment to related party	(1,501)
Interest income (expense), net	1,641	413	(4,594)
Other expense, net	(604)	(638)	(1,185)
Total non-operating income (expense)	(464)	(225)	(5,779)
Income (loss) before income taxes	11,484	(12,189)	(281,663)
Income taxes	2,231	1,074	579
Net income (loss)	9,253	(13,263)	(282,242)
Net income (loss) attributable to non-controlling interests	3,228	(5,609)	(123,925)
Net income (loss) attributable to Enfusion, Inc.	$ 6,025	$ (7,654)	$ (158,317)
Net income (loss) per Class A common shares attributable to Enfusion, Inc.:
Net income (loss) per share of Class A common stock--Basic	$ 0.07	$ (0.10)	$ (2.26)
Net income (loss) per share of Class A common stock--Diluted	$ 0.07	$ (0.10)	$ (2.26)
Weighted Average number of Class A common shares outstanding:
Weighted Average number of Class A common shares outstanding, Basic	88,202	85,393	83,045
Weighted Average number of Class A common shares outstanding, Diluted	129,429	85,393	83,045
Platform subscriptions
REVENUES:
Total revenues	$ 161,519	$ 138,868	$ 103,259
COST OF REVENUES:
Total cost of revenues	50,702	40,017	27,195
Managed services
REVENUES:
Total revenues	11,773	9,821	7,119
COST OF REVENUES:
Total cost of revenues	6,514	6,692	4,425
Other
REVENUES:
Total revenues	1,243	1,660	1,322
COST OF REVENUES:
Total cost of revenues	$ 425	$ 391	$ 225

ENFN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35,604	$ 62,545
Accounts receivable, net	28,069	25,855
Prepaid expenses	5,009	6,105
Other current assets	1,170	2,303
Total current assets	69,852	96,808
Property, equipment, and software, net	18,314	15,759
Right-of-use-assets, net	14,304	6,732
Other assets	6,502	4,484
Total assets	108,972	123,783
Current liabilities:
Accounts payable	2,212	1,685
Accrued expenses and other current liabilities	13,841	11,665
Current portion of lease liabilities	4,256	4,030
Total current liabilities	20,309	17,380
Lease liabilities, net of current portion	11,181	2,959
Total liabilities	31,490	20,339
Commitment and contingencies (Note 8)
Stockholders' Equity:
Preferred stock, $0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
Additional paid-in capital	226,877	244,260
Accumulated deficit	(172,932)	(178,863)
Accumulated other comprehensive loss	(406)	(504)
Total stockholders' equity attributable to Enfusion, Inc.	53,666	65,007
Non-controlling interests	23,816	38,437
Total stockholders' equity	77,482	103,444
Total liabilities and stockholders' equity	108,972	123,783
Common Class A
Stockholders' Equity:
Common stock	88	71
Common Class B
Stockholders' Equity:
Common stock	$ 39	$ 43

About Enfusion, Inc.

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.

CEO	Mr. Oleg Movchan
WEBSITE	enfusion.com
INDUSTRY	Software - Apps
EMPLOYEES	1006

Enfusion, Inc. Frequently Asked Questions

What is the ticker symbol for Enfusion, Inc.? What does ENFN stand for in stocks?

ENFN is the stock ticker symbol of Enfusion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enfusion, Inc. (ENFN)?

As of Thu May 02 2024, market cap of Enfusion, Inc. is 840.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENFN stock?

You can check ENFN's fair value in chart for subscribers.

What is the fair value of ENFN stock?

You can check ENFN's fair value in chart for subscribers. The fair value of Enfusion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enfusion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENFN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enfusion, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENFN is over valued or under valued. Whether Enfusion, Inc. is cheap or expensive depends on the assumptions which impact Enfusion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENFN.

What is Enfusion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, ENFN's PE ratio (Price to Earnings) is 139.51 and Price to Sales (PS) ratio is 4.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENFN PE ratio will change depending on the future growth rate expectations of investors.